Erick Lucera joined Beyond Air’s Board of Directors in August 2017. He was appointed Chief Financial Officer for AVEO Oncology, a NASDAQ traded biopharmaceutical company focused on targeted medicines for oncology and other unmet medical needs, in 2020. Mr. Lucera was most recently Chief Finanical Officer of Valeritas, a commercial-stage company developing new technology for diabetes. Prior to that, Mr. Lucera served as Chief Financial Officer, Treasurer, and Secretary of Viventia Bio. From 2012 to 2015, he was Vice President, Corporate Development at Aratana Therapeutics, a veterinary biopharmaceutical company. While at Aratana, he helped grow the company’s product pipeline through a series of acquisitions and in-licensing transactions financed through 5 public and private offerings of nearly $250 million. Before his career as a healthcare company executive, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital, and head of the healthcare research team at Independence Investments. He holds a CPH from Harvard University, a Master of Science in Quantitative Finance from Boston College, an MBA from Indiana University Bloomington, and a Bachelor of Science in Accounting from the University of Delaware. Mr. Lucera has obtained CFA, CMA, and CPA designations.